{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:24:09Z","timestamp":1770297849912,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,1,14]],"date-time":"2016-01-14T00:00:00Z","timestamp":1452729600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["1151.0014"],"award-info":[{"award-number":["1151.0014"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006056","name":"Stichting Cornelis Vrolijk Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006056","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Stichting Voorzieningenfonds Palliatieve Zorg Dirksland"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00228-015-2005-x","type":"journal-article","created":{"date-parts":[[2016,1,14]],"date-time":"2016-01-14T03:13:33Z","timestamp":1452741213000},"page":"459-467","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Treatment with subcutaneous and transdermal fentanyl: results from a population pharmacokinetic study in cancer patients"],"prefix":"10.1007","volume":"72","author":[{"given":"Astrid W.","family":"Oosten","sequence":"first","affiliation":[]},{"given":"Jo\u00e3o A.","family":"Abrantes","sequence":"additional","affiliation":[]},{"given":"Siv","family":"J\u00f6nsson","sequence":"additional","affiliation":[]},{"given":"Peter","family":"de Bruijn","sequence":"additional","affiliation":[]},{"given":"Evelien J. M.","family":"Kuip","sequence":"additional","affiliation":[]},{"given":"Am\u00edlcar","family":"Falc\u00e3o","sequence":"additional","affiliation":[]},{"given":"Carin C. D.","family":"van der Rijt","sequence":"additional","affiliation":[]},{"given":"Ron H. J.","family":"Mathijssen","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,1,14]]},"reference":[{"key":"2005_CR1","unstructured":"World Health Organisation. WHO\u2019s pain ladder for adults. Available at: http:\/\/www.who.int\/cancer\/palliative\/painladder\/en\/ . Accessed on September 26th 2015"},{"issue":"2","key":"2005_CR2","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","volume":"13","author":"A Caraceni","year":"2012","unstructured":"Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N et al (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13(2):e58\u2013e68","journal-title":"Lancet Oncol"},{"issue":"3","key":"2005_CR3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0304-3959(95)00180-8","volume":"64","author":"B Donner","year":"1996","unstructured":"Donner B, Zenz M, Tryba M, Strumpf M (1996) Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 64(3):527\u2013534","journal-title":"Pain"},{"issue":"1","key":"2005_CR4","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF00549460","volume":"263","author":"B Cube von","year":"1969","unstructured":"von Cube B, Teschemacher HJ, Herz A (1969) [A comparison of the analgetic action of intravenously and intraventricularly injected morphine-like substances, taking into account their fat solubility] Vergleich der analgetischen Wirkung morphinartiger Substanzen bei intravenoser und bei intraventrikularer Applikation in Hinblick auf ihre Lipoidloslichkeit. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 263(1):199\u2013200","journal-title":"Naunyn Schmiedebergs Arch Exp Pathol Pharmakol"},{"issue":"3","key":"2005_CR5","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1089\/jpm.2007.0200","volume":"11","author":"D Tassinari","year":"2008","unstructured":"Tassinari D, Sartori S, Tamburini E, Scarpi E, Raffaeli W, Tombesi P et al (2008) Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. J Palliat Med 11(3):492\u2013501","journal-title":"J Palliat Med"},{"key":"2005_CR6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1756-9966-29-67","volume":"29","author":"Q Yang","year":"2010","unstructured":"Yang Q, Xie DR, Jiang ZM, Ma W, Zhang YD, Bi ZF et al (2010) Efficacy and adverse effects of transdermal fentanyl and sustained-release oral morphine in treating moderate-severe cancer pain in Chinese population: a systematic review and meta-analysis. J Exp Clin Cancer Res 29:67","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"2005_CR7","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1185\/030079904X2114","volume":"20","author":"AJ Clark","year":"2004","unstructured":"Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U et al (2004) Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin 20(9):1419\u20131428","journal-title":"Curr Med Res Opin"},{"issue":"15","key":"2005_CR8","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.2165\/00003495-200161150-00014","volume":"61","author":"RB Muijsers","year":"2001","unstructured":"Muijsers RB, Wagstaff AJ (2001) Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 61(15):2289\u20132307","journal-title":"Drugs"},{"issue":"6","key":"2005_CR9","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1097\/00000542-198906000-00008","volume":"70","author":"JR Varvel","year":"1989","unstructured":"Varvel JR, Shafer SL, Hwang SS, Coen PA, Stanski DR (1989) Absorption characteristics of transdermally administered fentanyl. Anesthesiology 70(6):928\u2013934","journal-title":"Anesthesiology"},{"issue":"1","key":"2005_CR10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2125.2006.02758.x","volume":"63","author":"JF Marier","year":"2007","unstructured":"Marier JF, Lor M, Morin J, Roux L, Di Marco M, Morelli G et al (2007) Comparative bioequivalence study between a novel matrix transdermal delivery system of fentanyl and a commercially available reservoir formulation. Br J Clin Pharmacol 63(1):121\u2013124","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2005_CR11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejpb.2010.02.005","volume":"75","author":"HG Kress","year":"2010","unstructured":"Kress HG, Boss H, Delvin T, Lahu G, Lophaven S, Marx M et al (2010) Transdermal fentanyl matrix patches Matrifen and Durogesic DTrans are bioequivalent. Eur J Pharm Biopharm 75(2):225\u2013231","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"2005_CR12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0885-3924(98)00095-5","volume":"16","author":"S Watanabe","year":"1998","unstructured":"Watanabe S, Pereira J, Hanson J, Bruera E (1998) Fentanyl by continuous subcutaneous infusion for the management of cancer pain: a retrospective study. J Pain Symptom Manag 16(5):323\u2013326","journal-title":"J Pain Symptom Manag"},{"issue":"2","key":"2005_CR13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0885-3924(99)00051-2","volume":"18","author":"R Hunt","year":"1999","unstructured":"Hunt R, Fazekas B, Thorne D, Brooksbank M (1999) A comparison of subcutaneous morphine and fentanyl in hospice cancer patients. J Pain Symptom Manag 18(2):111\u2013119","journal-title":"J Pain Symptom Manag"},{"issue":"3","key":"2005_CR14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/01.NHH.0000347677.15617.ff","volume":"27","author":"M Justad","year":"2009","unstructured":"Justad M (2009) Continuous subcutaneous infusion: an efficacious, cost-effective analgesia alternative at the end of life. Home Healthc Nurse 27(3):140\u2013147, quiz 148\u20139","journal-title":"Home Healthc Nurse"},{"issue":"3","key":"2005_CR15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0304-3959(92)90034-9","volume":"50","author":"DF Zech","year":"1992","unstructured":"Zech DF, Grond SU, Lynch J, Dauer HG, Stollenwerk B, Lehmann KA (1992) Transdermal fentanyl and initial dose-finding with patient-controlled analgesia in cancer pain. A pilot study with 20 terminally ill cancer patients. Pain 50(3):293\u2013301","journal-title":"Pain"},{"issue":"1\u20132","key":"2005_CR16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0304-3959(96)03254-X","volume":"69","author":"S Grond","year":"1997","unstructured":"Grond S, Zech D, Lehmann KA, Radbruch L, Breitenbach H, Hertel D (1997) Transdermal fentanyl in the long-term treatment of cancer pain: a prospective study of 50 patients with advanced cancer of the gastrointestinal tract or the head and neck region. Pain 69(1\u20132):191\u2013198","journal-title":"Pain"},{"issue":"12","key":"2005_CR17","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1002\/1097-0142(20011215)92:12<3056::AID-CNCR10166>3.0.CO;2-H","volume":"92","author":"CA Kornick","year":"2001","unstructured":"Kornick CA, Santiago-Palma J, Khojainova N, Primavera LH, Payne R, Manfredi PL (2001) A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. Cancer 92(12):3056\u20133061","journal-title":"Cancer"},{"key":"2005_CR18","unstructured":"Beal SL, Sheiner LB, Boeckmann AJ, Bauer RJ (eds) (1989\u20132013) NONMEM 7.3.0 Users Guides. ICON Development Solutions, Hanover"},{"issue":"3","key":"2005_CR19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","volume":"79","author":"L Lindbom","year":"2005","unstructured":"Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-Toolkit\u2014a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Prog Biomed 79(3):241\u2013257","journal-title":"Comput Methods Prog Biomed"},{"issue":"2","key":"2005_CR20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN (2004) Perl-speaks-NONMEM (PsN)\u2014a Perl module for NONMEM related programming. Comput Methods Prog Biomed 75(2):85\u201394","journal-title":"Comput Methods Prog Biomed"},{"issue":"1","key":"2005_CR21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO (1999) Xpose\u2014an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Prog Biomed 58(1):51\u201364","journal-title":"Comput Methods Prog Biomed"},{"issue":"6","key":"2005_CR22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF01113502","volume":"21","author":"MO Karlsson","year":"1993","unstructured":"Karlsson MO, Sheiner LB (1993) The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 21(6):735\u2013750","journal-title":"J Pharmacokinet Biopharm"},{"issue":"1","key":"2005_CR23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","volume":"82","author":"MO Karlsson","year":"2007","unstructured":"Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82(1):17\u201320","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2005_CR24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143\u2013151","journal-title":"AAPS J"},{"issue":"1","key":"2005_CR25","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/clpt.1980.138","volume":"28","author":"DA McClain","year":"1980","unstructured":"McClain DA, Hug CC Jr (1980) Intravenous fentanyl kinetics. Clin Pharmacol Ther 28(1):106\u2013114","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"2005_CR26","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00520-010-0890-1","volume":"19","author":"M Nomura","year":"2011","unstructured":"Nomura M, Kamata M, Kojima H, Hayashi K, Kozai M, Sawada S (2011) Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study. Support Care Cancer 19(5):691\u2013695","journal-title":"Support Care Cancer"},{"issue":"2","key":"2005_CR27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3109\/15360288.2012.679725","volume":"26","author":"H Kokubun","year":"2012","unstructured":"Kokubun H, Ebinuma K, Matoba M, Takayanagi R, Yamada Y, Yago K (2012) Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain. J Pain Palliat Care Pharmacother 26(2):98\u2013104","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"2005_CR28","doi-asserted-by":"crossref","unstructured":"Bista SR, Haywood A, Hardy J, Norris R, Hennig S (2015) Exposure to fentanyl after transdermal patch administration for cancer pain management. J Clin Pharmacol","DOI":"10.1002\/jcph.641"},{"issue":"4","key":"2005_CR29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/01.ftd.0000160717.50704.42","volume":"27","author":"I Solassol","year":"2005","unstructured":"Solassol I, Bressolle F, Caumette L, Garcia F, Poujol S, Culine S et al (2005) Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients. Ther Drug Monit 27(4):491\u2013498","journal-title":"Ther Drug Monit"},{"issue":"1","key":"2005_CR30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000542-199301000-00007","volume":"78","author":"RK Portenoy","year":"1993","unstructured":"Portenoy RK, Southam MA, Gupta SK, Lapin J, Layman M, Inturrisi CE et al (1993) Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiology 78(1):36\u201343","journal-title":"Anesthesiology"},{"issue":"6","key":"2005_CR31","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1177\/0091270006286901","volume":"46","author":"JF Marier","year":"2006","unstructured":"Marier JF, Lor M, Potvin D, Dimarco M, Morelli G, Saedder EA (2006) Pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects. J Clin Pharmacol 46(6):642\u2013653","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"2005_CR32","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5414\/CP201901","volume":"52","author":"J Liu","year":"2014","unstructured":"Liu J, Zhou X (2014) Bioequivalence assessment of two transdermal delivery systems of fentanyl in healthy Chinese volunteers. Int J Clin Pharmacol Ther 52(2):175\u2013180","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"2005_CR33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bcp.12595","volume":"80","author":"E Zecca","year":"2015","unstructured":"Zecca E, Manzoni A, Centurioni F, Farina A, Bonizzoni E, Seiler D et al (2015) Pharmacokinetic study between a bilayer matrix fentalyl patch and a monolayer matrix fentanyl patch: single dose administration in healthy volunteers. Br J Clin Pharmacol 80(1):110\u2013115","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2005_CR34","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00520-010-0825-x","volume":"19","author":"DY Kim","year":"2010","unstructured":"Kim DY, Song HS, Ahn JS, Ryoo BY, Shin DB, Yim CY et al (2010) The dosing frequency of sustained-release opioids and the prevalence of end-of-dose failure in cancer pain control: a Korean multicenter study. Support Care Cancer 19(2):297\u2013301","journal-title":"Support Care Cancer"},{"issue":"1","key":"2005_CR35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003088-200038010-00004","volume":"38","author":"S Grond","year":"2000","unstructured":"Grond S, Radbruch L, Lehmann KA (2000) Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet 38(1):59\u201389","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"2005_CR36","first-page":"553","volume":"40","author":"RS Miller","year":"1995","unstructured":"Miller RS, Peterson GM, Abbott F, Maddocks I, Parker D, McLean S (1995) Plasma concentrations of fentanyl with subcutaneous infusion in palliative care patients. Br J Clin Pharmacol 40(6):553\u2013556","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2005_CR37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/EJA.0b013e328331a361","volume":"27","author":"SJ Capper","year":"2010","unstructured":"Capper SJ, Loo S, Geue JP, Upton RN, Ong J, Macintyre PE et al (2010) Pharmacokinetics of fentanyl after subcutaneous administration in volunteers. Eur J Anaesthesiol 27(3):241\u2013246","journal-title":"Eur J Anaesthesiol"},{"issue":"6","key":"2005_CR38","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/AJP.0b013e318266f6a5","volume":"29","author":"M Nomura","year":"2013","unstructured":"Nomura M, Inoue K, Matsushita S, Takahari D, Kondoh C, Shitara K et al (2013) Serum concentration of fentanyl during conversion from intravenous to transdermal administration to patients with chronic cancer pain. Clin J Pain 29(6):487\u2013491","journal-title":"Clin J Pain"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-2005-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-015-2005-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-015-2005-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T15:07:43Z","timestamp":1553612863000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-015-2005-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,14]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["2005"],"URL":"https:\/\/doi.org\/10.1007\/s00228-015-2005-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,14]]}}}